A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC
BackgroundThe current standard approach to the treatment of patients with non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)—sensitizing mutations has been the treatment with a first-generation EGFR-TKIs. While, with resistance develope...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
AIMS Press
2019-06-01
|
Series: | Mathematical Biosciences and Engineering |
Subjects: | |
Online Access: | https://www.aimspress.com/article/10.3934/mbe.2019283?viewType=HTML |